CMTA is leading a coordinated CMT1A research strategy that connects disease models, drug development, biomarkers, delivery science, and clinical infrastructure to accelerate new treatments.
CMTA Fuels Breakthrough Imaging Research to Address CMT2A’s Cellular Weakness
CMTA announced a $90,860 CMTA-STAR investment supporting advanced imaging research to examine how MFN2 mutations disrupt cellular transport in CMT2A.
Tiny Movers, Big Clues: Dr. Manor Uses AI to Shed Light on CMT2A
CMTA-funded CMT2A treatment research at UC San Diego is building the tools to develop ASO therapies targeting the faulty MFN2 gene, with a clear path toward treatments.
CMTA’s Commitment to The Inherited Neuropathy Consortium
CMTA strengthens its role as the leading force in comprehensive CMT research, forging a strategic...
